Tumor targeting via EPR: Strategies to enhance patient responses.

The tumor accumulation of nanomedicines relies on the enhanced permeability and retention (EPR) effect. In the last 5-10 years, it has been increasingly recognized that there is a large inter- and intra-individual heterogeneity in EPR-mediated tumor targeting, explaining the heterogeneous outcomes of clinical trials in which nanomedicine formulations have been evaluated. To address this heterogeneity, as in other areas of oncology drug development, we have to move away from a one-size-fits-all tumor targeting approach, towards methods that can be employed to individualize and improve nanomedicine treatments. To this end, efforts have to be invested in better understanding the nature, the complexity and the heterogeneity of the EPR effect, and in establishing systems and strategies to enhance, combine, bypass and image EPR-based tumor targeting. In the present manuscript, we summarize key studies in which these strategies are explored, and we discuss how these approaches can be employed to enhance patient responses.

[1]  D. Jaffray,et al.  APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[2]  A. Witkamp,et al.  Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. , 2001, Cancer treatment reviews.

[3]  J. Sozanski,et al.  Temperature control and thermal dosimetry by microwave radiometry in hyperthermia , 1996 .

[4]  A. Jimeno,et al.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Tayyaba Hasan,et al.  Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications , 2006, Clinical Cancer Research.

[6]  Benjamin J Vakoc,et al.  Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging , 2009, Nature Medicine.

[7]  Michael R Hamblin,et al.  Scavenger-Receptor Targeted Photodynamic Therapy¶ , 2000, Photochemistry and photobiology.

[8]  C. Moonen,et al.  Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. , 2017, Advanced drug delivery reviews.

[9]  Xian-feng Ding,et al.  Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice , 2017, Journal of Zhejiang University-SCIENCE B.

[10]  K. Hori,et al.  Fluctuations in Tumor Blood Flow under Normotension and the Effect of Angiotensin II‐induced Hypertension , 1991, Japanese journal of cancer research : Gann.

[11]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[12]  P. O'Connor,et al.  Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.

[13]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[14]  Fabian Kiessling,et al.  Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. , 2014, Nano letters.

[15]  H. Maeda,et al.  Tumor‐selective Blood Flow Decrease Induced by an Angiotensin Converting Enzyme Inhibitor, Temocapril Hydrochloride , 2000, Japanese journal of cancer research : Gann.

[16]  H. Maeda,et al.  Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. , 2009, Japanese journal of clinical oncology.

[17]  Mauro Ferrari,et al.  Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. , 2014, Cancer research.

[18]  Alexander L. Klibanov,et al.  Microbubbles in ultrasound-triggered drug and gene delivery. , 2008, Advanced drug delivery reviews.

[19]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[20]  T. Okinaga,et al.  Local delivery system of cytotoxic agents to tumors by focused sonoporation , 2007, Cancer Gene Therapy.

[21]  H. Dvorak,et al.  Why are tumour blood vessels abnormal and why is it important to know? , 2009, British Journal of Cancer.

[22]  Rolf Bjerkvig,et al.  In vivo models of primary brain tumors: pitfalls and perspectives , 2012, Neuro-oncology.

[23]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[24]  B. Henderson,et al.  SITES OF PHOTODAMAGE in vivo and in vitro BY A CATIONIC PORPHYRIN , 1995, Photochemistry and photobiology.

[25]  S. Libutti,et al.  Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. , 2012, Journal of vascular and interventional radiology : JVIR.

[26]  Tetsurou Yamamoto,et al.  Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue , 1988, Japanese journal of cancer research : Gann.

[27]  G. Storm,et al.  Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant. , 2016, Nanomedicine.

[28]  Nathan McDannold,et al.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. , 2014, Advanced drug delivery reviews.

[29]  D. Tarin,et al.  Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. , 2011, Bioconjugate chemistry.

[30]  H. Dvorak Discovery of vascular permeability factor (VPF). , 2006, Experimental cell research.

[31]  M. V. van Zandvoort,et al.  PBCA‐based polymeric microbubbles for molecular imaging and drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Triantafyllos Stylianopoulos,et al.  Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors , 2012, Proceedings of the National Academy of Sciences.

[33]  M. May Cancer research with a human touch , 2018, Nature.

[34]  Khaled Greish,et al.  Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? , 2012, Drug discovery today. Technologies.

[35]  T. Lagerweij,et al.  Human pontine glioma cells can induce murine tumors , 2014, Acta Neuropathologica.

[36]  F. Kiessling,et al.  Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[37]  V. Préat,et al.  RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.

[38]  C. Curtis,et al.  Organoids reveal cancer dynamics , 2018, Nature.

[39]  R. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Muschel,et al.  Drug radiotherapy combinations: review of previous failures and reasons for future optimism. , 2015, Cancer treatment reviews.

[41]  Fabian Kiessling,et al.  Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy , 2010 .

[42]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[43]  O. Kaidar-Person,et al.  Application of nanotechnology to cancer radiotherapy , 2016, Cancer Nanotechnology.

[44]  Zahi A. Fayad,et al.  Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy , 2016, Nature Communications.

[45]  M. Dewhirst,et al.  Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. , 2001, Cancer research.

[46]  Wei He,et al.  Core-shell nanocarriers with high paclitaxel loading for passive and active targeting , 2016, Scientific Reports.

[47]  Takahiro Nomoto,et al.  Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. , 2013, ACS nano.

[48]  M. Dewhirst,et al.  Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.

[49]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Hongyu,et al.  IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. , 2015, ACS nano.

[51]  Ralph Weissleder,et al.  Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.

[52]  Betty Y. S. Kim,et al.  Lessons from immuno-oncology: a new era for cancer nanomedicine? , 2017, Nature Reviews Drug Discovery.

[53]  W. Dewey,et al.  Hyperthermia and radiation--a selective thermal effect on chronically hypoxic tumor cells in vivo. , 1977, International journal of radiation oncology, biology, physics.

[54]  T. Hagemann,et al.  Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. , 2015, Cancer cell.

[55]  R. Lencioni,et al.  RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. , 2016, Hepatic oncology.

[56]  A. Molven,et al.  A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[57]  T. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[58]  Kinam Park To PEGylate or not to PEGylate, that is not the question. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[59]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[60]  P. Choyke,et al.  Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. , 2013, ACS nano.

[61]  K. Hynynen,et al.  Thermosensitive nanomedicines could revolutionize thermal therapy in oncology , 2017 .

[62]  S. Libutti,et al.  Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. , 2002, Blood.

[63]  G. Winter,et al.  New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[64]  R. Jain,et al.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.

[65]  Jian Cao,et al.  Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas , 2015, Genes & diseases.

[66]  M. Dewhirst,et al.  Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma. , 2018, JAMA oncology.

[67]  F. Danhier,et al.  To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[68]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[69]  K. Ulbrich,et al.  Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. , 2013, Biomaterials.

[70]  O. Kaalhus,et al.  Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts , 2004, Cancer Research.

[71]  Eduardo G. Moros,et al.  Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: A prospectively controlled randomized study by the radiation therapy oncology group , 1993 .

[72]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[73]  David J. Waxman,et al.  Multi‐modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[74]  Tuan Vo-Dinh,et al.  Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers , 2017, Scientific Reports.

[75]  M. V. van Zandvoort,et al.  Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[76]  Xiaoyuan Chen,et al.  Rethinking cancer nanotheranostics. , 2017, Nature reviews. Materials.

[77]  M. V. van Zandvoort,et al.  Theranostic USPIO‐Loaded Microbubbles for Mediating and Monitoring Blood‐Brain Barrier Permeation , 2015, Advanced functional materials.

[78]  Ashish Ranjan,et al.  Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[79]  Miles A. Miller,et al.  Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts , 2017, Science Translational Medicine.

[80]  M. Dewhirst,et al.  Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. , 2012, Cancer research.

[81]  M. Hidalgo,et al.  SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts , 2016, Molecular Cancer Therapeutics.

[82]  David Kessel,et al.  Photodynamic therapy of cancer: An update , 2011, CA: a cancer journal for clinicians.

[83]  P. Choyke,et al.  The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy , 2013, Molecular Cancer Therapeutics.

[84]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[85]  K. Kinzler,et al.  A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles , 2011, Oncotarget.

[86]  M. Bally,et al.  Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.

[87]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  F. Kiessling,et al.  Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[89]  Y. Matsumura Cancer stromal targeting (CAST) therapy. , 2012, Advanced drug delivery reviews.

[90]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[91]  Zhijian J. Chen,et al.  A STING-Activating Nanovaccine for Cancer Immunotherapy , 2017, Nature nanotechnology.

[92]  Karen Campbell,et al.  64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[93]  S. Noguchi,et al.  Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma , 1988, Cancer.

[94]  D. K. Ways,et al.  Effect of Ionizing Radiation on AP-1 Binding Activity and Basic Fibroblast Growth Factor Gene Expression in Drug-sensitive Human Breast Carcinoma MCF-7 and Multidrug-resistant MCF-7/ADR Cells * , 1995, The Journal of Biological Chemistry.

[95]  B. Alman,et al.  Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood. , 2017, ACS nano.

[96]  R. Korn,et al.  Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.

[97]  E. Voest,et al.  Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery. , 2017, Cell chemical biology.

[98]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[99]  J. Erler,et al.  Targeting ECM Disrupts Cancer Progression , 2015, Front. Oncol..

[100]  F. Szoka,et al.  Macrophage-based cell therapies: The long and winding road. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[101]  R. Jain,et al.  Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.

[102]  E. Unanue,et al.  Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. , 1991, Journal of immunology.

[103]  Tracy T Batchelor,et al.  Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. , 2012, Cancer research.

[104]  R. Goldberg,et al.  Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience. , 2015 .

[105]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[106]  Y. Matsumura,et al.  New concept of cytotoxic immunoconjugate therapy targeting cancer‐induced fibrin clots , 2011, Cancer science.

[107]  T. Hongo,et al.  Angiotensin‐Induced Hypertension Chemotherapy in Children with Advanced Solid Tumors , 1991, Acta paediatrica Japonica : Overseas edition.

[108]  Rakesh K. Jain,et al.  Pathology: Cancer cells compress intratumour vessels , 2004, Nature.

[109]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[110]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[111]  L Tupchong,et al.  Randomized Phase III Study Comparing Irradiation and Hyperthermia with Irradiation Alone in Superficial Measurable Tumors: Final Report by the Radiation Therapy Oncology Group , 1991, American journal of clinical oncology.

[112]  P Wust,et al.  Simulation studies promote technological development of radiofrequency phased array hyperthermia. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[113]  Fabian Kiessling,et al.  Micro-CT Imaging of Tumor Angiogenesis Quantitative Measures Describing Micromorphology and Vascularization , 2014 .

[114]  K. Ulbrich,et al.  Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy , 2008, British Journal of Cancer.

[115]  Jeffrey A. Engelman,et al.  Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.

[116]  Kwangmeyung Kim,et al.  Engineering nanoparticle strategies for effective cancer immunotherapy. , 2018, Biomaterials.

[117]  Mark W Dewhirst,et al.  Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. , 2007, Journal of the National Cancer Institute.

[118]  A. Deal,et al.  Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[119]  R. Weichselbaum,et al.  Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. , 2016, Journal of the American Chemical Society.

[120]  F. Kiessling,et al.  Recent advances in ultrasound-based diagnosis and therapy with micro- and nanometer-sized formulations. , 2017, Methods.

[121]  M. Caligiuri,et al.  Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever‐like) whole body hyperthermia , 1998, Journal of cellular physiology.

[122]  K. Leong,et al.  Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. , 2016, Biomaterials.

[123]  Ralph R. Weichselbaum,et al.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.

[124]  I. Hsu,et al.  Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer , 2014, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[125]  Rakesh K. Jain,et al.  Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels , 2013, Nature Communications.

[126]  G. Calais,et al.  Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma. , 1999, Journal of the National Cancer Institute.

[127]  Lawrence Mayer,et al.  In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.

[128]  D. Ribatti,et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.

[129]  Qin Xu,et al.  Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy. , 2016, ACS applied materials & interfaces.

[130]  R. Mertelsmann,et al.  Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  J. Verweij,et al.  Renal toxicities of chemotherapy. , 2006, Seminars in Oncology.

[132]  J. Isola,et al.  Trastuzumab emtansine: mechanisms of action and drug resistance , 2014, Breast Cancer Research.

[133]  L. Cardoso,et al.  Quantification of transient increase of the blood–brain barrier permeability to macromolecules by optimized focused ultrasound combined with microbubbles , 2014, International journal of nanomedicine.

[134]  Giridhar Thiagarajan,et al.  Nanoparticle toxicity assessment using an in vitro 3-D kidney organoid culture model. , 2014, Biomaterials.

[135]  Mark E. Davis,et al.  Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles , 2009, Proceedings of the National Academy of Sciences.

[136]  L. Mayer,et al.  Optimizing combination chemotherapy by controlling drug ratios. , 2007, Molecular interventions.

[137]  A. Eggermont,et al.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.

[138]  Chiara Brignole,et al.  Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. , 2006, Cancer research.

[139]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[140]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[141]  R K Jain,et al.  Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. , 1999, Cancer research.

[142]  Natalia Vykhodtseva,et al.  Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. , 2012, Ultrasound in medicine & biology.

[143]  K Hynynen,et al.  Ultrasound technology for hyperthermia. , 1999, Ultrasound in medicine & biology.

[144]  J. Kopeček,et al.  Biological rationale for the design of polymeric anti-cancer nanomedicines , 2013, Journal of drug targeting.

[145]  F. Kiessling,et al.  Balancing Passive and Active Targeting to Different Tumor Compartments Using Riboflavin-Functionalized Polymeric Nanocarriers. , 2017, Nano letters.

[146]  Horst Kessler,et al.  Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.

[147]  Paul Workman,et al.  How Much Longer Will We Put Up With $100,000 Cancer Drugs? , 2017, Cell.

[148]  F. Greco,et al.  Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection. , 2017, Journal of pharmaceutical sciences.

[149]  Paul A. Dayton,et al.  Optical observation of lipid- and polymer-shelled ultrasound microbubble contrast agents , 2004 .

[150]  Jennifer I. Hare,et al.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.

[151]  H. Maeda,et al.  Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. , 1993, British Journal of Cancer.

[152]  K. Hakamada,et al.  International Journal of Molecular Sciences the Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma , 2022 .

[153]  J. Cortes,et al.  Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. , 2016 .

[154]  Zhigang Wang,et al.  Antitumor Effect of Docetaxel‐Loaded Lipid Microbubbles Combined With Ultrasound‐Targeted Microbubble Activation on VX2 Rabbit Liver Tumors , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[155]  A. Eggermont,et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[157]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[158]  Wen Jiang,et al.  Designing nanomedicine for immuno-oncology , 2017, Nature Biomedical Engineering.

[159]  Triantafyllos Stylianopoulos,et al.  Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.

[160]  Kevin J. Harrington,et al.  The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence , 2015, Nature Reviews Cancer.

[161]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  P. Stayton,et al.  Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[163]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[164]  K. Greish,et al.  Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots , 2013 .

[165]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[166]  Brian Seed,et al.  Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.

[167]  Karl Deisseroth,et al.  Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity , 2017, Nature Biomedical Engineering.

[168]  Fabian Kiessling,et al.  Cancer nanomedicine: Is targeting our target? , 2016, Nature reviews. Materials.

[169]  G. Duigou,et al.  Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways , 2001, Oncogene.

[170]  R. Jain,et al.  Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. , 1996, Cancer research.

[171]  S. Eberhardt,et al.  Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[172]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[173]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[174]  A. Giatromanolaki,et al.  High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy. , 2000, Acta oncologica.

[175]  G. Batist,et al.  A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC) , 2008 .

[176]  M. Kester,et al.  Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[177]  M. Ferrari,et al.  Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. , 2017, Seminars in immunology.

[178]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[179]  H. Maeda Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[180]  Anang A. Shelat,et al.  Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors , 2017, Nature.

[181]  Rogério Gaspar,et al.  Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking , 2014, Front. Chem..

[182]  R. Jain,et al.  Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. , 1993, Cancer research.

[183]  Takashi Nakamura,et al.  Integration of nano drug-delivery system with cancer immunotherapy. , 2017, Therapeutic delivery.

[184]  Yechezkel Barenholz,et al.  Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs , 1993, Pharmaceutical Research.

[185]  A. Nel,et al.  New Insights into "Permeability" as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics. , 2017, ACS nano.

[186]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[187]  Laurence Zitvogel,et al.  Mouse models in oncoimmunology , 2016, Nature Reviews Cancer.

[188]  U. Klingmüller,et al.  Erythropoietin Improves the Accumulation and Therapeutic Effects of Carboplatin by Enhancing Tumor Vascularization and Perfusion , 2015, Theranostics.

[189]  H. Verheul,et al.  The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGFReceptor Kinase Inhibitors , 2000 .

[190]  K. Ulbrich,et al.  Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[191]  Bradford J. Wood,et al.  Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model , 2012, PloS one.

[192]  M. Amichetti,et al.  Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. , 1994, International journal of radiation oncology, biology, physics.

[193]  M. Halyard,et al.  Benefits, risks, and safety of external beam radiation therapy for breast cancer , 2015, International journal of women's health.

[194]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[195]  V. Gebski,et al.  First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials , 2017, The Lancet. Oncology.

[196]  P. Peschke,et al.  Morphometric analysis of bromodeoxyuridine distribution and cell density in the rat Dunning prostate tumor R3327-AT1 following treatment with radiation and/or hyperthermia. , 1999, Histology and histopathology.

[197]  J. Baselga,et al.  Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[198]  Hans Clevers,et al.  Intra-tumour diversification in colorectal cancer at the single-cell level , 2018, Nature.

[199]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[200]  Khaled Greish,et al.  Nanomedicine: is it lost in translation? , 2018, Therapeutic delivery.

[201]  A. Dudley Tumor endothelial cells. , 2012, Cold Spring Harbor perspectives in medicine.

[202]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[203]  K. Berg,et al.  THE PHOTODEGRADATION OF PORPHYRINS IN CELLS CAN BE USED TO ESTIMATE THE LIFETIME OF SINGLET OXYGEN , 1991, Photochemistry and photobiology.

[204]  N. Ferrara,et al.  VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.

[205]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[206]  J. Kolitz,et al.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  D. Kessel,et al.  Mitochondrial photodamage and PDT-induced apoptosis. , 1998, Journal of photochemistry and photobiology. B, Biology.

[208]  Timothy W. Secomb,et al.  Transport of drugs from blood vessels to tumour tissue , 2017, Nature Reviews Cancer.

[209]  E. Barbier,et al.  An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors , 2016, Scientific Reports.

[210]  Hiroshi Maeda,et al.  Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs , 2018, Clinical and Translational Medicine.

[211]  H. Maeda,et al.  Tumor-Targeted Macromolecular Drug Delivery Based on the Enhanced Permeability and Retention Effect in Solid Tumor , 2009 .

[212]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[213]  F. Kiessling,et al.  Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. , 2016, Drug discovery today. Technologies.

[214]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[215]  Ashley M. Laughney,et al.  Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.

[216]  Z. Duan,et al.  Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model , 2008, Molecular pharmaceutics.

[217]  B. Hendriks,et al.  Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines , 2018, Theranostics.

[218]  D. Sica,et al.  Clinical Pharmacokinetics of Losartan , 2005, Clinical pharmacokinetics.